KR20220017919A - 펩티드 핵산을 기반으로 한 아쥬반트 - Google Patents

펩티드 핵산을 기반으로 한 아쥬반트 Download PDF

Info

Publication number
KR20220017919A
KR20220017919A KR1020217039788A KR20217039788A KR20220017919A KR 20220017919 A KR20220017919 A KR 20220017919A KR 1020217039788 A KR1020217039788 A KR 1020217039788A KR 20217039788 A KR20217039788 A KR 20217039788A KR 20220017919 A KR20220017919 A KR 20220017919A
Authority
KR
South Korea
Prior art keywords
adjuvant
peptide
administration
nucleic acid
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217039788A
Other languages
English (en)
Korean (ko)
Inventor
료타로 미츠마타
아스미 간다
Original Assignee
덴카 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 덴카 주식회사 filed Critical 덴카 주식회사
Publication of KR20220017919A publication Critical patent/KR20220017919A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217039788A 2019-06-06 2020-06-05 펩티드 핵산을 기반으로 한 아쥬반트 Withdrawn KR20220017919A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019106444 2019-06-06
JPJP-P-2019-106444 2019-06-06
PCT/JP2020/022293 WO2020246584A1 (ja) 2019-06-06 2020-06-05 ペプチド核酸を基盤としたアジュバント

Publications (1)

Publication Number Publication Date
KR20220017919A true KR20220017919A (ko) 2022-02-14

Family

ID=73652763

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217039788A Withdrawn KR20220017919A (ko) 2019-06-06 2020-06-05 펩티드 핵산을 기반으로 한 아쥬반트

Country Status (8)

Country Link
US (1) US12016920B2 (https=)
EP (1) EP3981426A4 (https=)
JP (1) JP7602457B2 (https=)
KR (1) KR20220017919A (https=)
CN (1) CN113939313B (https=)
AU (1) AU2020288030A1 (https=)
TW (1) TW202112394A (https=)
WO (1) WO2020246584A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230157429A (ko) 2021-04-07 2023-11-16 덴카 주식회사 애주번트 활성 증강제 및 애주번트 조성물
JP2023128573A (ja) * 2022-03-03 2023-09-14 デンカ株式会社 腸管へのウイルス特異的な抗体誘導が可能なノロウイルスワクチン

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206749B1 (en) 1999-02-26 2012-06-26 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1279404A1 (en) * 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
ITMI20030860A1 (it) * 2003-04-29 2004-10-30 Univ Bologna Metodo per l'inibizione selettiva del gene n-myc
ZA200707967B (en) 2005-04-08 2008-11-26 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
WO2009126933A2 (en) * 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
US9562228B2 (en) * 2012-09-14 2017-02-07 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of MYC by double-stranded RNA
MX374090B (es) * 2013-03-14 2025-03-05 Caribou Biosciences Inc Composiciones y métodos de ácidos nucleicos dirigidos al ácido nucleico.
US20160206715A1 (en) 2013-03-15 2016-07-21 Bullet Biotechnology, Inc. Specific multivalent virus-like particle vaccines and uses thereof
US9902973B2 (en) * 2013-04-11 2018-02-27 Caribou Biosciences, Inc. Methods of modifying a target nucleic acid with an argonaute
WO2018013924A1 (en) * 2016-07-15 2018-01-18 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Marichal T, Ohata K, Bedoret D, Mesnil C, Sabatel C, Kobiyama K, Lekeux P, Coban C, Akira S, Ishii KJ, Bureau F, Desmet CJ. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med. 2011 Jul 17 ; 17 (8) : 996 - 1002.

Also Published As

Publication number Publication date
JP7602457B2 (ja) 2024-12-18
TW202112394A (zh) 2021-04-01
WO2020246584A1 (ja) 2020-12-10
AU2020288030A1 (en) 2022-01-06
EP3981426A1 (en) 2022-04-13
EP3981426A4 (en) 2023-06-07
CN113939313B (zh) 2024-11-01
JPWO2020246584A1 (https=) 2020-12-10
US12016920B2 (en) 2024-06-25
CN113939313A (zh) 2022-01-14
US20230330221A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
ES3058501T3 (en) Rsv f protein mutants
ES2312465T3 (es) Peptidos de vih de regiones conservadas en gag p17 y sus aplicaciones, tales como vacunas.
ES2741729T3 (es) Vectores y construcciones de liberación de antígenos de virus de la gripe
ES2858315T3 (es) Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
KR102777000B1 (ko) 인플루엔자 바이러스 백신 및 이의 용도
ES2790527T3 (es) Composiciones de vacunas contra el síndrome reproductivo y respiratorio porcino y las enfermedades asociadas al circovirus porcino
WO2010045613A1 (en) Immunoenhancer-linked oligomeric hiv vaccines
JP2023540486A (ja) 免疫原性コロナウイルス融合タンパク質および関連方法
KR20220017919A (ko) 펩티드 핵산을 기반으로 한 아쥬반트
KR20250140108A (ko) 호흡기 세포융합 바이러스 mRNA 백신
WO2005002500A2 (en) Inhibitors of coronavirus
JP2018052837A (ja) エボラウイルスワクチン
US20190337989A1 (en) Immunity inducer
US20240207395A1 (en) Adjuvant activity enhancer and adjuvant composition
US20240226272A9 (en) Immunogenic compositions
Asakura et al. Th1-biased immune responses induced by DNA-based immunizations are mediated via action on professional antigen-presenting cells to up-regulate IL-12 production
JP2024545833A (ja) コロナウイルス科ウイルスによる感染症の処置または予防のためのウイルス様粒子
JP2019528071A (ja) 新規免疫刺激ペプチド
RU2845190C2 (ru) Вирусоподобные частицы cmv, модифицированные путем слияния
US20220125913A1 (en) SYNTHETIC PEPTIDES, AMINO-ACID SEQUENCES, AND COMPOSITIONS USEFUL FOR SARS-CoV-2 DETECTION AND COVID-19 PREVENTION
WO2022173302A1 (en) Immunogenic polypeptides and pharmaceutical compositions
US20220401546A1 (en) HIV Immunogens, Vaccines, and Methods Related Thereto
EP4370681A1 (en) Influenza virus-based isolated recombinant virus
WO2025137448A1 (en) T cell-based sars-cov-2 vaccine
OA21734A (en) Influenza virus-based isolated recombinant virus.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

B11 Application withdrawn

Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B11-NAP-PC1202 (AS PROVIDED BY THE NATIONAL OFFICE)

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202